Tower Research Capital (TRC)’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,654
| Closed | -$5.81K | – | 6174 |
|
|
2024
Q1 | $5.81K | Sell |
3,654
-8,028
| -69% | -$11.9K | ﹤0.01% | 4484 |
|
|
2023
Q4 | $10K | Sell |
11,682
-16,216
| -58% | -$14.2K | ﹤0.01% | 4306 |
|
|
2023
Q3 | $29.9K | Buy |
27,898
+23,850
| +589% | +$49.4K | ﹤0.01% | 3027 |
|
|
2023
Q2 | $10.5K | Sell |
4,048
-723
| -15% | -$2.58K | ﹤0.01% | 4114 |
|
|
2023
Q1 | $19K | Buy |
4,771
+1,719
| +56% | +$7.95K | ﹤0.01% | 3521 |
|
|
2022
Q4 | $16K | Sell |
3,052
-2,622
| -46% | -$16.4K | ﹤0.01% | 3390 |
|
|
2022
Q3 | $74K | Buy |
5,674
+3,441
| +154% | +$52.1K | ﹤0.01% | 2832 |
|
|
2022
Q2 | $29K | Buy |
2,233
+1,218
| +120% | +$16.9K | ﹤0.01% | 3426 |
|
|
2022
Q1 | $16K | Buy |
1,015
+279
| +38% | +$4.35K | ﹤0.01% | 3775 |
|
|
2021
Q4 | $13K | Sell |
736
-5,499
| -88% | -$106K | ﹤0.01% | 4223 |
|
|
2021
Q3 | $131K | Buy |
6,235
+3,442
| +123% | +$75.8K | ﹤0.01% | 2171 |
|
|
2021
Q2 | $55K | Buy |
2,793
+1,091
| +64% | +$25.5K | ﹤0.01% | 2957 |
|
|
2021
Q1 | $49K | Buy |
1,702
+465
| +38% | +$13K | ﹤0.01% | 3151 |
|
|
2020
Q4 | $37K | Sell |
1,237
-4,953
| -80% | -$108K | ﹤0.01% | 3407 |
|
|
2020
Q3 | $98K | Buy |
6,190
+2,276
| +58% | +$41.5K | ﹤0.01% | 3162 |
|
|
2020
Q2 | $77K | Buy |
3,914
+2,590
| +196% | +$49.5K | ﹤0.01% | 2694 |
|
|
2020
Q1 | $16K | Buy |
+1,324
| New | +$21.6K | ﹤0.01% | 1831 |
|
|
2019
Q3 | – | Sell |
-1,072
| Closed | -$16K | – | 4622 |
|
|
2019
Q2 | $16K | Buy |
+1,072
| New | +$15.7K | ﹤0.01% | 2311 |
|
Tower Research Capital (TRC)'s NGM Position: Q2 2024 in Review
Tower Research Capital (TRC) sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 3,654 shares — an estimated $5.81K sold.
Tower Research Capital (TRC) first reported a position in NGM in Q2 2019 and held it in 18 quarters. The position peaked at $131K in Q3 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Tower Research Capital (TRC) reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Tower Research Capital (TRC) sold 3,654 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $5.81K.
- Tower Research Capital (TRC) first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 18 quarters.
- Tower Research Capital (TRC)'s NGM Biopharmaceuticals, Inc. Common Stock position peaked at $131K in Q3 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.